KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Depreciation and Depletion (2020 - 2024)

Historic Depreciation and Depletion for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q4 2024 value amounting to -$14.0 million.

  • Aurinia Pharmaceuticals' Depreciation and Depletion fell 12930.47% to -$14.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $600000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $600000.0 for FY2024, which is 0.0% changed from last year.
  • Aurinia Pharmaceuticals' Depreciation and Depletion amounted to -$14.0 million in Q4 2024, which was down 12930.47% from $4.9 million recorded in Q3 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Depreciation and Depletion peaked at $5.3 million during Q3 2023, and registered a low of -$14.0 million during Q4 2024.
  • Its 5-year average for Depreciation and Depletion is $96421.1, with a median of $687000.0 in 2022.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 563333.33% in 2021, then plummeted by 22315.85% in 2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $154000.0 in 2020, then crashed by 987.66% to -$1.4 million in 2021, then tumbled by 38.04% to -$1.9 million in 2022, then tumbled by 223.16% to -$6.1 million in 2023, then tumbled by 129.3% to -$14.0 million in 2024.
  • Its Depreciation and Depletion stands at -$14.0 million for Q4 2024, versus $4.9 million for Q3 2024 and $4.8 million for Q2 2024.